Search results
Results From The WOW.Com Content Network
Genome Therapeutics Corporation. Genome Therapeutics Corp. was an early biotech company. It was founded in 1961 by Orrie M. Friedman under the name Collaborative Research Inc. [1] Under the leadership of Helen Donis-Keller and using internal funds, the company produced one of the first linkage maps of the whole human genome in the mid-1980s.
Gemifloxacin. Gemifloxacin mesylate, sold under the brand name Factive among others, is a broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is taken by mouth.
Oscient Pharmaceuticals Corp. (OSCI) said Monday it and its wholly owned subsidiary, Guardian II Acquisition Corporation, each filed for Chapter 11 bankruptcy protection in the United States ...
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
June 10, 2024 at 6:38 PM. By Puyaan Singh and Mariam Sunny. (Reuters) -The U.S. Food and Drug Administration granted accelerated approval to French drugmakers Ipsen and Genfit's drug for a chronic ...
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases . Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic uremic ...
Riot, the biggest shareholder in Bitfarms with a nearly 15% stake, withdrew the offer on Monday but said it was "ready to engage" with the company's reconstituted board about a potential transaction.